January 2026 in “Experimental Dermatology” Keratinocytes contribute to hidradenitis suppurativa by causing inflammation and worsening the condition.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
June 2025 in “British Journal of Dermatology” Dupilumab can cause psoriasis in some patients.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
49 citations
,
August 2022 in “Frontiers in Immunology” Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.
28 citations
,
January 2017 in “EBioMedicine” Enhancing cannabinoid signaling may help treat skin inflammation.
12 citations
,
May 2024 in “Indian Dermatology Online Journal” Probiotics may help treat skin conditions like acne and eczema safely.
8 citations
,
February 2022 in “Vascular Health and Risk Management” Some skin conditions may increase the risk of heart disease, and understanding their connection could lead to better treatments.
7 citations
,
May 2025 in “Journal of Biomedical Science” Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.
5 citations
,
April 2022 in “Evidence-based Complementary and Alternative Medicine” Shaoyao Gancao decoction may treat alopecia areata by affecting the PI3K/AKT signaling pathway.
1 citations
,
July 2022 in “Indian Journal of Dermatology” Bullous pyoderma gangrenosum can develop on cesarean scars and may require steroids for treatment.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
December 2025 in “International Journal of Molecular Sciences” Exosome-based therapies show promise for treating alopecia areata but need more research.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
August 2025 in “Frontiers in Microbiology” Microneedling, especially with halometasone, improves hair regrowth and gut health in alopecia areata.
409 citations
,
May 1991 in “Genes & Development” TGF-alpha affects skin thickness, hair growth, and may contribute to psoriasis and papilloma formation.
286 citations
,
June 2012 in “Nature Immunology” Hair follicles help attract immune cells to the skin during stress.
98 citations
,
March 2019 in “Frontiers in immunology” Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.
54 citations
,
September 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Vitamin A affects hair loss and immune response in alopecia areata.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
50 citations
,
January 2013 in “Indian Journal of Dermatology” Some skin conditions, like psoriasis and early-onset baldness, may indicate metabolic syndrome, and others are linked to diabetes risk and cardiovascular issues.
20 citations
,
August 2020 in “Stem Cell Research & Therapy” miR-150 helps blood vessel cells develop and speeds up blood clot healing.
10 citations
,
April 2024 in “International Journal of Molecular Sciences” Gut bacteria differences may influence alopecia areata.
9 citations
,
January 2021 in “Mediators of Inflammation” 15d‐PGJ2 cream protects against UVB-induced skin damage in mice.
5 citations
,
May 2017 in “Journal of dermatological science” The combined treatment effectively managed severe skin issues in Olmsted syndrome.
4 citations
,
July 2019 in “Experimental Dermatology” 2-deoxy D-glucose does not help with hair regrowth in alopecia areata.
3 citations
,
April 2021 in “Cureus” Low Vitamin D is common in people with Alopecia Areata, but its impact on the condition needs more research.
2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors, such as guselkumab, tildrakizumab, and risankizumab, are primarily approved for psoriasis but show potential for off-label use in treating various inflammatory skin conditions like hidradenitis suppurativa, lichen planus, and frontal fibrosing alopecia. While some case reports and small studies, including one with 69 patients with hidradenitis suppurativa, indicate significant improvements in symptoms and quality of life, the evidence remains limited. Larger, randomized clinical trials are needed to confirm the efficacy and safety of these inhibitors for off-label dermatologic uses. The safety profile is generally favorable, with upper respiratory tract infections being the most common side effect.
1 citations
,
December 2025 in “Photodermatology Photoimmunology & Photomedicine” Phototherapy effectively treats certain alopecia areata types, especially if started early.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.